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Abstract
Background: Seizures in up to one third of children with epilepsy may not be controlled by the first anti-epileptic
drug (AED). In this study, we describe multiple AED usage in children attending a referral clinic in Uganda, the
factors associated with multiple AED use and seizure control in affected patients.
Methods: One hundred thirty nine patients attending Mulago hospital paediatric neurology clinic with epilepsy
and who had been on AEDs for ≥6 months were consecutively enrolled from July to December 2013 to reach the
calculated sample size. With consent, the history and physical examination were repeated and the neurophysiologic
and imaging features obtained from records. Venous blood was also drawn to determine AED drug levels. We
determined the proportion of children on multiple AEDs and performed regression analyses to determine factors
independently associated with multiple AED use.
Results: Forty five out of 139 (32.4 %) children; 46.7 % female, median age 6 (IQR = 3–9) years were on multiple
AEDs. The most common combination was sodium valproate and carbamazepine. We found that 59.7 % of children
had sub-therapeutic drug levels including 42.2 % of those on multi-therapy. Sub-optimal seizure control (adjusted
odds ratio [ORa] 3.93, 95 % CI 1.66–9.31, p = 0.002) and presence of focal neurological deficits (ORa 3.86, 95 % CI
1.31–11.48, p = 0.014) were independently associated with multiple AED use but not age of seizure onset, duration
of epilepsy symptoms, seizure type or history of status epilepticus.
Conclusion: One third of children with epilepsy in Mulago receive multiple AEDs. Multiple AED use is most
frequent in symptomatic focal epilepsies but doses are frequently sub-optimal. There is urgent need to improve
clinical monitoring in our patients.
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Background
Epilepsy contributes 10 % of the global burden of brain
disorders [1], and is associated with considerable mor-
bidity and mortality [2] and poor quality of life. World-
wide, up to 80 million people are affected of whom 10.5
million are children <15 years [3]. In Uganda, the esti-
mated prevalence of epilepsy is 10 · 3 (9 · 5-11 · 1) per
1000 population [4] and the age specific prevalence rate
in children <15 years is 2.0 % [5].
Despite its debilitating effects, over 70 % of patients
can attain good seizure control with appropriate treat-
ment. The goal of treatment is restoration of near nor-
mal life with complete seizure control using a single
anti-epileptic drug (AED). Monotherapy is recom-
mended because of fewer adverse drug effects, absence
of drug-drug interactions, better compliance, and lower
cost compared to therapy with multiple AEDs [6–9].
Studies in developed countries with adequate resources
for treatment have however shown that 17-40 % of chil-
dren do not respond to the first drug used and may re-
quire multiple AEDs [10, 11]. It has been suggested that
the patients’ clinical characteristics such as frequent,
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focal and long duration of seizures, symptomatic or syn-
dromic epilepsy, history of status epilepticus, and the
presence of neurological deficits, is the primary reason
for failure of the first AED, rather than drug related fac-
tors such as efficacy and adverse effects. The answers to
these questions are important, because inadequate re-
sponse to initial treatment with the first AED and subse-
quent treatment with multiple AEDs is believed, in itself,
to be a poor prognostic factor in epilepsy [12–14].
The main objective of the study was to determine the
use of multiple AEDs and associated factors among chil-
dren attending a referral clinic in Uganda.
Methods
Study design
This was a cross sectional descriptive study of one hun-
dred thirty nine children with epilepsy attending Mulago
hospital in Kampala, Uganda.
Setting
The study was carried out in the paediatric neurology
clinic (PNC) at Mulago hospital in Kampala, Uganda.
Mulago hospital is a public hospital located 2 km from
the city center and serves as a National Referral for the
entire country and a general hospital as well as Health
Center IV, III for the Kampala metropolitan area (Ugan-
da’s capital city) with an official bed capacity of 1790. It
also serves as a teaching hospital for Makerere Univer-
sity College of Health Sciences. The PNC is under the
Department of Paediatrics and Child Health and is run
as an outpatient specialized clinic which caters to chil-
dren with neurological disorders once a week every
Thursday between 8 am – 3 pm. It serves as a referral
outpatient clinic for the neurological cases from all over
the country. Annually the clinic sees about 300 new pa-
tients and on each clinic day 25 – 40 children with ages
ranging from 2 months to 18 years are attended to; the
clinic´s upper age limit is 16 but there are older patients
who have not yet been transferred to the adult clinic.
Epilepsy is the most common diagnosis in 68.4 % of the
children attending the PNC. Patients are seen by a team
comprised of a paediatric neurologist, paediatricians,
residents, nurses and a records clerk. Children seen in
this clinic are referrals from paediatric wards and other
hospitals around the country with a few self-referrals. Ser-
vices provided include; clinical evaluation and care, refer-
rals to specialized clinics, laboratory tests- HIV rapid test,
blood slide for malaria parasites and haemoglobin estima-
tion. Other investigations such as renal function and liver
function tests, limited biochemical tests and other specific
tests are done in the hospital’s main laboratory. Serum
drug level tests are not done at the hospital but may be
sourced at a fee from privately run laboratories. Investiga-
tions such as Electro encephalogram (EEG) and CT scans
are also carried out in the hospital at a cost. Magnetic res-
onance imaging (MRI) is available outside the hospital for
patients who can afford it.
In Uganda, treatment is offered free of charge in all
health centers. Both a national treatment guideline and a
national list of essential medicines exist to aid the health
personnel in the management of epilepsy but these are
not readily available even at this clinic. Most epilepsy pa-
tients receive the older generation AEDs which are given
after consultation with a paediatric neurologist but the
choice of drug eventually given is usually based on avail-
ability. These AEDs might be initiated as part of the
hospitalization or at the provider’s discretion before re-
ferrals to the PNC are made and may require adjust-
ments during the clinic visits. Subsequent increment of
doses and use of additional AEDs is usually at the pre-
scriber’s discretion. Patients requiring some of the new
generation AEDs have to source for these privately at a
cost. Patients are given appointments of 2 weeks up to
3 months based on seizure control and also to monitor
the side effects of the AEDs.
Participants
The study included participants with a diagnosis of epi-
lepsy (two or more unprovoked seizures); aged <18 years;
had received AEDs for at least six months before enrol-
ment into the study and whose parents or guardians
provided written informed consent. In addition, chil-
dren older than eight years and without severe mental
retardation provided assent. Acutely ill children re-
quiring hospitalization and children being treated
with any of newer generation AEDs (lamotrigine, le-
vetiracetam, vigabatrin and topiramate) were excluded
due to limitations in measuring the serum drug levels
in the country.
Sample size
The sample size was estimated using the Daniel 1999
formula for finite populations and was based on a preva-
lence multiple drug use of 20 % by Carpay et al. [15] A
sample size of 136 patients was attained.
Study procedures
The study was approved by Makerere University School
of Medicine Research and Ethics Committee, reference
2013–063.
a) Recruitment
On each clinic day from July to December 2013,
patients with epilepsy and fulfilling the study
eligibility criteria were approached for possible
participation and those with consenting parents/
guardians were consecutively enrolled. Unattended
minors were given consent forms to take home and
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asked to return them on scheduled appointment
dates when they were interviewed with their
parents/guardians.
b) Data collection
For the history, information from patient’s records
was abstracted on to a case record form. This was
supplemented by direct inquiry. Data thus collected
included the socio-demographic characteristics,
specific clinical details such as age of onset of
seizures, seizure types, frequency and duration,
epilepsy diagnosis,, possible risk factors in the birth
and past medical history, and AED history (type of
drugs, doses, adverse events, duration of treatment,
treatment response, and adherence). In addition,
reports of electroencephalographic (EEG) recordings
and brain imaging (computerized tomography [CT]
and magnetic resonance imaging [MRI] scans) and
the conclusions from these reports e.g. the clinical
classification of the epilepsy were abstracted when
available. Seizures were broadly categorized according
to the 2010 International League against Epilepsy
(ILAE) criteria into generalized, focal and unclassified
type seizures [15].
A physical examination was performed to assess the
nutritional status, identify neurological deficits;
describe function and concurrent co-morbidities.
The height and weight was measured, patients had
an examination for peripheral stigmata of central
nervous system disease and a comprehensive
examination of all systems. The neurologic examination
documented the mental status, assessed the cranial
nerves and motor deficits and classified this using a
topographical classification system – (monoparesis,
diplegia, hemiparesis or quadriparesis). Abnormalities
of movement and coordination such as tremors,
chorea, athetosis, dystonia, gait and ataxia were also
recorded.
c) Determination of drug levels
Two mls of venous blood was drawn from a
peripheral vein to determine the drug levels at study
enrolment. The collected sample was placed into plain
vacutainer tubes between 9.00 am and 1.00 pm on the
day of enrolment. The samples were then transported
on ice to the Lancet laboratories, an internationally
accredited laboratory by the South African National
Accreditation System (SANAS) for analysis within
8 hours of collection. In the laboratory, the samples
were centrifuged at 3000 rpm for 10 minutes and sera
collected. The serum levels of all the older generation
AEDs (carbamazepine, phenobarbitone and sodium
valproate) were then determined using a Fluorescence
Polarization Immunoassay (FPIA) method using
COBAS® 4000 analyzer, Roche Diagnostics. The FPIA
method offers significant advantages in calibration
curve stability while maintaining accuracy and
precision comparable with those of established HPLC
procedures. The individual therapeutic range of
carbamazepine was 34–51 μmol/l when used as
monotherapy and 17–34 μmol/l if it was part of a
combination therapy. For phenobarbitone, the
therapeutic range was 43–172 μmol/l while for
sodium valproate this was 347–693 μmol/l
irrespective of whether each was being used alone
or as part of combination therapy [16–18].
Data management and analysis
The case record forms were cross- checked for com-
pleteness before end of the day and the data entered into
an Epidata version 3.1(Odense, Denmark) database. Data
was analyzed using STATA version 12.0, (STATA Cor-
poration, TX). The proportion of children being treated
with multiple AED was determined. In examining fac-
tors associated with the use of multiple AED as opposed
to monotherapy, categorical variables were summarized
as proportions/percentages and compared using the chi-
square test or fisher’s exact test. Normally distributed
continuous data were summarized using the mean with
standard deviations and compared using the student’s t
test while the median was used for skewed data. Vari-
ables with p-values ≤ 0.2 at bivariate analysis were sub-
jected to logistic regression analysis to identify factors
independently associated with multiple AED therapy. A
p-value ≤ 0.05 was considered statistically significant. To
examine the relationship between multiple AED use and
seizure control we used the chi square test for trends to
analyze the differences in the frequency of seizures in
children on monotherapy compared to those on multiple
AED therapy. Good seizure control was defined as ≤ 1
seizure in the previous 6 months.
Results
General descriptions
A total of 215 children aged less than 18 years attending
the neurology clinic during the study period were
screened. The majority (163/215, 75.8 %) had epilepsy.
Twenty four epilepsy patients were excluded; 23 had
been on treatment for less than six months and 1 was
being treated with lamotrigine. We subsequently en-
rolled 139 children into this study. The median age of
the participants was 6 (IQR 4–10) years; 78/139 (56 %)
were male; the median age of onset of seizures was 1
(IQR 0.3 – 4) years and the median duration of seizures
was 4 (IQR 2 – 5) years (Table 1).
Patterns of epilepsy
Based on EEGs, generalized epilepsy was described in
49/125 (39.2 %) children; 57.1 % were male with a me-
dian age of 6 (IQR = 4 – 8) years. Focal epilepsy in 59/
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125 (47.2 %) children; 50.8 % were male with a median
age of 7 (IQR = 4 – 12) years while 17/125 (13.6 %) had
epileptic syndromes; 58.8 % were male with a median
age of 4 (IQR = 3 – 7) years. (13 - Lennox-Gastaut syn-
drome, 2 - Infantile spasms and 2 - Benign Rolandic epi-
lepsy). Fourteen children did not have EEG tracings or
reports. Overall epilepsy was symptomatic or probably
symptomatic in 95/139 (68.4 %) participants, idiopathic
in 11/139 (7.9 %) and cryptogenic in 33/139 (23.7 %).
Patients were considered to have symptomatic or prob-
ably symptomatic epilepsy if they had a history of known
or suspected risk factor for epilepsy. Idiopathic epilepsy
was considered for those with epileptic syndromes
without a history of known or suspected risk factor.
These included; absence epilepsy, benign rolandic epi-
lepsy with centrotemporal spikes and myoclonic epi-
lepsy. Cryptogenic epilepsy was considered for those
who did not meet the criteria for idiopathic or symp-
tomatic categories [19].
Neurological impairments among the study participants
The study participants were assessed for development
delay, visual, motor and hearing impairments. Ninety
four children (67.6 %) had a neurological deficit; 42 % fe-
male, median age 5.5 (IQR = 3 – 8) years. Seventy nine
Table 1 Demographics of study participants
Characteristics Multi therapy Mono therapy Odds Ratio
N = 45 (%) N = 94 (%) (95 % CI)
Male 24 (53.4) 54 (57.5) 1
Female 21 (46.6) 40 (42.5) 1.18 (0.58 – 2.41)
0 – 1 years 2 (4.5) 6 (6.4) 1
2 – 6 years 23 (51.1) 42 (44.7) 1.64 (0.31 – 8.81)
6 – 13 years 18 (40.0) 38 (40.4) 1.42 (0.26 – 7.75)
14 – 18 years 2 (4.4) 8 (8.5) 0.75 (0.08 – 6.96)
Primary caretaker
Mother 30 (66.6) 66 (70.2) 1
Father 6 (13.3) 11 (11.7) 1.20 (0.41 – 3.55)
Grandparent 1 (2.2) 8 (8.5) 0.28 (0.03 – 2.30)
Uncle/Aunt 5 (11.1) 6 (6.4) 1.83 (0.52 – 6.48)
Other 3 (6.8) 3 (3.2) 2.20 (0.42 – 11.54)
District
Kampala 11 (24.4) 28 (29.8) 1
Wakiso 22 (48.9) 46 (48.9) 1.22 (0.51 – 2.88)
Others 12 (26.7) 20 (21.3) 1.53 (0.56 – 4.15)
Guardian Education Level
No formal education 4 (8.9) 3 (3.3) 1
Primary level 19 (42.2) 38 (41.3) 0.38 (0.08 – 1.85)
Secondary level 13 (28.9) 43 (46.7) 0.23 (0.04 – 1.15)
Tertiary institution 9 (20.0) 8 (8.7) 0.84 (0.14 – 4.97)
Mother employment
Unemployed 25 (55.6) 36 (39.2) 1
Casual laborer 3 (6.7) 4 (4.4) 1.08 (0.22 – 5.25)
Self-employed 11 (24.4) 42 (45.6) 0.38 (0.16 – 0.87)
Formally employed 6 (13.3) 10 (10.8) 0.86 (0.28 – 2.68)
Household monthly income
Less than100,000 9 (19.9) 27 (28.7) 1
100,000 - 200,000 12 (26.7) 26 (27.7) 1.38 (0.50 – 3.83)
200,000 - 500,000 12 (26.7) 16 (17.0) 2.25 (0.78 – 6.51)
Greater than 500,000 12 (26.7) 25 (26.6) 1.44 (0.52 – 4.00)
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children 79/94 (84.0 %) had developmental delay in at
least one field; gross motor, fine motor, speech/language
and social skills. The frequency of participants with a
single impairment was thirty three 33/94 (35.1 %),
(Fig. 1).
Use of multiple anti-epileptic drugs
Forty five of the 139 children (32.4 %) were on multiple
AED; 42 were on dual therapy while three were on triple
therapy. The most common drug combination was so-
dium valproate and carbamazepine, 34/45 (75.5 %)
followed by carbamazepine and phenobarbitone, 6/45
(13.4 %) and sodium valproate and phenobarbitone, 2/45
(4.5 %). Of the 94/139 participants on monotherapy, 54/
139 (38.8 %) were on carbamazepine only, 37/139
(26.6 %) were on sodium valproate only, two were on
phenobarbitone and one was on phenytoin only. Regard-
ing seizure control; thirteen children on multi AED ther-
apy, 13/45 (28.9 %) had good seizure control compared
to 61/94 (64.9 %) patients on monotherapy.
Clinical characteristics and multiple anti-epileptic drug
use
At bivariate analysis, patients with poor seizure control
(defined as ≥ 1 seizure in past 6 months), the presence of
a neurological deficit and a history of status epilepticus
were more likely to be using multiple AED therapy
(Table 2).
Treatment history and multiple anti-epileptic drug use
Children initially treated with two drugs (17/139, p =
0.016) were more likely to be using multiple AEDs while
children using sodium valproate alone were less likely to
be on multiple drugs, (Table 3).
Anti-epileptic drug therapy
i. Doses of first anti-epileptic drug used
On average, children using multiple AEDs were
prescribed a smaller dose of their first AED
compared to children on monotherapy; sodium
valproate – median dose 12 mg/kg/day (IQR 10–25)
vs. 18.5 mg/kg/day (IQR 10–29), carbamazepine –
median dose 13 mg/kg/day (IQR 10–20) vs. 10 mg/
kg/day vs. 13 mg (IQR 5.5-16) and Phenobarbitone
2 mg/kg/day (IQR 2–7.5) vs. 4 mg/kg/day (IQR
2.5-7.5). The differences in drug doses were not
statistically significant between the two groups.
ii. Prescribed drug doses and serum drug levels for
children on multi-therapy
The most commonly used drug in this study
population for both monotherapy and multi-therapy
was carbamazepine. Regarding those on multi-
therapy, forty two children 42/45 (93.3 %) were
using carbamazepine in their drug combinations; 36/
45 were on carbamazepine and sodium valproate, 4/
45 were on carbamazepine and phenobarbitone
while 2/45 were on carbamazepine, sodium valproate
Fig. 1 Distribution of neurological impairments among the study participants. Majority of the children had developmental delays (n = 79) compared
to motor (n = 33) and visual impairment (n = 28)
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Table 2 Clinical characteristics of study participants
Variables Outcome Unadjusted Odds
ratio (CI)
p-value
Multi therapy N = 45 (%) Mono therapy N = 94 (%)
Age at onset <1 year 22 (48.9) 35 (37.2) 1.61 (0.79 - 3.31) 0.193
≥1 year 23 (51.1) 59 (62.8) 1
Duration of epilepsy <2 years 4 (8.9) 17 (18.1) 1
≥2 years 41 (91.1) 77 (81.9) 2.26 (0.71 – 7.17) 0.165
Seizure patterna Generalized 12 (29.3) 37 (41.7) 1
Focal 24 (58.5) 35(41.7) 2.11 (0.92 – 4.86) 0.078
Epileptic syndrome 5 (12.2) 12 (14.3) 1.28 (0.38 – 4.39) 0.690
Seizure frequencyb ≥1seizure/day 29 (64.5) 45 (47.9) 1
≥1 seizure/week 2 (4.5) 10 (10.6) 0.32 (0.06 – 1.55)
≥1 seizure/month 10 (22.2) 29 (30.9) 0.53 (0.23 – 1.24) 0.317
≤1 seizure/year 4 (8.8) 10 (10.6) 0.63 (0.18 – 2.21)
Neurological deficit No 5 (11.1) 40 (42.5) 1
Yes 40 (88.9) 54 (57.5) 5.93 (2.15 – 16.36) <0.001
Symptomatic epilepsy No 11 (24.4) 33 (35.1) 1
Yes 34 (75.6) 61 (64.9) 1.67 (0.75 – 3.73) 0.240
Prior history of status epilepticus No 28 (62.2) 75 (79.8) 1
Yes 17 (37.8) 19 (20.2) 2.40 (1.09 – 5.26) 0.027
Family history of epilepsy No 30 (66.7) 75 (79.8) 1
Yes 15 (33.3) 19 (20.2) 1.97 (0.89 – 4.39) 0.092
Seizure control Good 13 (28.9) 61 (64.9) 1
Poor 32 (71.1) 33 (35.1) 4.55 (2.10 – 9.84) <0.001
a125 children had EEG records bSeizure frequency before initiation of treatment
Table 3 Treatment history of study participants
Variables Outcome Unadjusted OR
(95 % CI)
P-value*
Multi therapy 45 (%) Mono therapy 94 (%)
Time to seek treatment <1 week 3 (6.7) 10 (10.6) 1
1 Week < 1 month 6 (13.3) 6 (6.4) 3.33 (0.59 – 18.5) 0.336
1 Month < 1 year 13 (28.9) 37 (39.4) 1.14 (0.27 – 4.79)
≥1 year 23 (51.1) 41 (43.6) 1.82 (0.46 – 7.31)
First treatment point Government health center 4 (8.9) 3 (3.2) 1
General hospital 4 (8.9) 1 (1.1) 4 (0.29 – 53.5) 0.065
National referral hospital 33 (73.3) 79 (84.0) 0.41 (0.10 – 1.75)
Private clinic 4 (8.9) 6 (6.4) 0.67 (0.10 – 4.35)
Traditional healer 0 (0.0) 5 (5.3) -
Initial no. of drugs given to the child One 35 (77.8) 87 (92.6) 1
Two 10 (22.2) 7 (7.4) 3.55 (1.25 – 10.07) 0.013
Child using Valproate Yes 9 (20.0) 37 (39.4) 0.39 (0.17 – 0.89) 0.023
No 36 (80.0) 57 (60.6) 1
Other medications Yes 4 (8.9) 12 (12.8) 1
No 41 (91.1) 82 (87.2) 1.46 (0.44 – 4.82) 0.503
*Fisher’s exact test was used where we had a cell count less than 5
- Inestimable
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and phenobarbitone. Overall, the majority of
children 83/139 (59.7 %) had sub-therapeutic serum
drug levels including 19/45 42.2 % of those on
multi-therapy. However, since it has an established
dose–drug level relationship and because of its
frequent use, we determined and used serum levels
of carbamazepine as a representative of other drugs
in analysis. There was variability in drug doses and
serum drug levels in children using multi-therapy
(Fig. 2). A total of only 11 children 11/42 (26.2 %)
were receiving adequate maintenance drug doses.
Seventeen children, 17/42 (40.5 %) had drug levels
below the therapeutic range. Of these children; none
had a higher than recommended drug dose, seven
were receiving the recommended maintenance drug
dose while 10 were receiving a dose lower than the
recommended maintenance drug dose.
Thirteen children 13/42 (31.0 %) had drug levels
within the therapeutic range. Of these; one child was
on the recommended maintenance drug dose,
another had a higher than recommended drug dose
while 11 children were on lower than the
recommended maintenance drug doses. In addition,
12 children 12/42 (28.5 %) had drug levels above the
therapeutic range. Of these; 2 had higher than
recommended drug doses, 3 were receiving
recommended maintenance drug doses and 7 had
less than the recommended drug doses. Only one
child (2.4 %) was on both the recommended
maintenance drug dose and had drug levels within
the therapeutic range.
iii. Adherence to anti-epileptic drug therapy
Adherence was assessed using a self-report of a
three, seven and 28 day- recall. The mean adherence
was 82.7 %. There was no statistically significant
difference in adherence between children using
monotherapy and those on multi AED. However, the
majority of caretakers 93/139 (66.9 %) reported that
at least on one occasion during the course of their
child’s treatment, drugs were not available either in
the clinic’s pharmacy or the hospital’s central
pharmacy where medications are provided at no cost
necessitating purchase from either drug shops or
private pharmacies.
iv. Side effect profile
Caretakers of thirty two 32/139 (23.0 %) children
reported their child had ever experienced a side
effect while on treatment with AEDs however at the
time of the survey based on symptoms and
examination, no child had clinically evident adverse
events. Side effects previously experienced included;
nausea/vomiting – 5, headache – 9, drowsiness – 8,
hyperactivity – 2, abdominal discomfort – 3,
impaired school performance – 5.
Factors associated with multiple anti-epileptic drug therapy
On bivariate analysis, poor seizure control defined as
one or more seizures in the previous six months (p <
0.001), a focal neurological deficit (p < 0.001), history of
status epilepticus (p = 0.027), initiation on AED treat-
ment with two drugs (p = 0.016), and treatment with so-
dium valproate (p = 0.023) were associated with multiple
AED but only poor seizure control (ORa 3.93 95 % CI
1.66 – 9.31, p = 0.002) and presence of a focal neuro-
logical deficit (ORa 3.86 95 % CI 1.31 – 11.48, p = 0.014)
were independently associated with using multiple
AEDs. Children using sodium valproate (ORa 0.28 95 %
CI 0.11 – 0.71, p = 0.007) were less likely to be using
multiple AED therapy.
Seizure control in children using anti-epileptic drug
therapy
Children using multi AEDs had a higher number of daily
seizures compared to children on mono therapy. Chil-
dren on multi AED were also less likely to have attained
good seizure control (p < 0.001), (Fig. 3).
Discussion
We set out to describe multiple AED use in our
clinic. The study found that 1/3 children with epi-
lepsy in the clinic were on multiple AEDs which
was also associated with poor seizure control and
the presence of focal neurologic deficits. Although
Fig. 2 Scatter plot of Carbamazepine drug doses vs. drug levels. The
majority of the study participants has sub-optimal drug levels despite
taking the recommended drug doses. a – Minimum therapeutic dose
of carbamazepine. b – Maximum therapeutic dose of carbamazepine.
c – Maximum dose recommended for carbamazepine. d – Minimum
dose recommended for carbamazepine. Recommended maximum
maintenance dose for Carbamazepine is 20 – 25 mg/kg; the
therapeutic range for Carbamazepine combination therapy is
16.8 – 33.8 μmol/l
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adherence was reported as good, the majority of pa-
tients had sub-therapeutic serum drug levels.
The frequency of multiple AED use in this cohort is
similar to that described in two previous European
studies [20, 21] but markedly less than the 50 % in a
Scottish study that included both children and adults
[22]. It is possible that in some of our patients, the
second AED could have been introduced too early
since on average, children using multi-therapy in our
study received a lower dose of the first AED compared
to children on mono-therapy. This may have been due
to prescribers not realizing the need to gradually in-
crease the dose of the first AED before tapering off
and introducing a second AED before managing chil-
dren with two or more drugs. There are country
guidelines for the management of epilepsy with rec-
ommended drugs and doses for each seizure type but
these do not emphasize monotherapy and even then
are not readily available, not even in the PNC which is
in a national referral hospital. In addition, there is
usually no continuity of care since senior house offi-
cers run the clinic on a rotational basis. There is evi-
dence that optimizing the dose of monotherapy AEDs
may control seemingly refractory cases of epilepsy
[23]. If some of our patients were prematurely initi-
ated on multiple AED therapy then our study could
have overestimated the number of children who actu-
ally require multi AEDs to control their seizures. This
has an impact on adherence, drug-drug interactions
with the potential of increased adverse effects, in-
creased costs and the probability that seizures may not
be controlled even with multiple drug use [24].
Factors associated with use of multiple AED
therapy
Clinical characteristics
Seizure onset in the majority of our patients was in the
first year of life and the median duration of seizures at
the time of the study was four years. Based on the clin-
ical, neurophysiologic and imaging features, 2/3 of the
patients had symptomatic or probably symptomatic
epilepsy. These findings are similar to those in several
cohorts in Africa and in other developing countries and
have been attributed to a higher incidence of acquired
brain injury from adverse perinatal events and CNS in-
fections in resource limited settings [4, 25]. The associ-
ation of multi AED use with focal neurologic signs or
symptomatic or probably symptomatic epilepsy is also
consistent with other studies around the world in
which children with such seizures were less likely to
achieve seizure control with the first attempt at mono-
therapy [13, 20, 26].
Anti-epileptic drugs
We observed that children initiated on sodium valproate
as the first line AED were less likely to be using multiple
AED. This may be attributed to the fact that carbamaze-
pine was the first line AED in patients with the poten-
tially more difficult to treat symptomatic seizures (hence
a higher potential of treatment failure). However, the
same could have been due to the broad spectrum nature
of sodium valproate. Sodium valproate has demonstrated
efficacy in the treatment of an array of seizure types in-
cluding; generalized idiopathic seizures, focal seizures,
and epileptic syndromes like Lennox-Gastaut [27]. Two
Fig. 3 Seizure frequency on therapy. Participants on multi-therapy with AEDs were less likely to have≤ 2 seizures in the past year compared to
participants on monotherapy (p < 0001)
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hospital based studies in the USA demonstrated that
children with focal seizures and in particular, those with
secondary generalization had improved seizure control
after sodium valproate was introduced as monotherapy
despite failing on earlier attempts with carbamazepine,
phenytoin and phenobarbitone [28, 29]. Another study
in the same country also demonstrated that patients
with co-morbid neurological impairments could success-
fully be weaned off multiple AED therapy to sodium val-
proate monotherapy [30].
Association between multiple drug use and seizure
control
Study participants managed with multiple AEDs were al-
most four times more likely to have poor seizure control
compared to those using monotherapy; 29 % reported
good seizure control. This may have been due to the
high frequency of focal seizures and the high rates of
symptomatic epilepsy which may be due to underlying
brain structural abnormalities. In addition, inadequate
drug doses with sub-therapeutic serum drug levels might
also have contributed to the poor seizure control in our
patients. Proper education of health care providers re-
garding adequate dosing and side effect monitoring for
AEDs is required to address issues of low dose polyther-
apy among people living with epilepsy. Advocating and
engaging ministry of health to ensure that appropriate
AEDs are readily available, introduction of newer broad
spectrum AEDS such as Levetiracetam and the introduc-
tion of health insurance or cost sharing may help mitigate
these challenges. Inadequate control of seizures increases
the risk of social ostracism and stigmatization especially in
low resource settings. In many African countries, epilepsy
is still considered contagious and supernatural powers are
often quoted as its cause. As a result, parents often seek
spiritual healing before seeking medical care and may con-
tinue to do so even while their children are in care often
times missing appointments and drugs, which in addition
to lack of resources for transport to the hospital and the
purchase of necessary drugs may adversely affect follow
up and treatment outcomes [31].
Study limitations
First, the study partly relied on participant recall to assess
seizure control and self-report to assess adherence to
AEDs. However, the presence of definite serum drug levels
would have limited these effects. Secondly, formal assess-
ments for hearing, vision, speech and language impair-
ments were not carried out systematically in all patients
but only in selected patients where concern had been
expressed. This could have led to an under representation
of patients with neurological impairment. Thirdly, treat-
ment is provided freely at all public health facilities within
the country, the prescribed drugs depend on the available
class and majority of our patients lack out of pocket funds
to maintain adequate dosing.
Conclusions
One third of children with epilepsy attending the epilepsy
clinics at Mulago hospital are being managed with mul-
tiple Anti-Epileptic drug therapy. However many of these
children might have been inappropriately initiated onto
multiple AEDs as they were on lower than recommended
maintenance doses. This might be related to lack of ad-
equate AED supply and availability in our settings. Train-
ing health workers to use appropriate treatment
guidelines and recommended drugs and their doses, pa-
tient education, the use objective measures of adherence
monitoring and increased access to monitoring drug levels
may improve the rational use AEDs and seizure control.
Strategies are also required to support the continuous
availability of supplies of AEDs and to increase the range
of anti-epilepsy treatment options in the country.
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